这项研究的目的是评估在秃鹰(BAEAs)(Haliaeetusleucocephalus)中以10和20mg/kg的剂量肌内给药的头孢噻呋晶型游离酸(CCFA)的药代动力学特性。头孢噻呋结晶游离酸是一种长效,可注射,第三代头孢菌素类抗生素药物。一个潜在的,随机化,本药代动力学研究采用完全交叉设计.肌内给药CCFA(10或20mg/kg),血液样本来自6名成年人,不可释放,健康的BAEAs在预定的采样时间。经过4周的冲洗期,根据随机交叉设计,每只接受初始样本收集期间未给予的剂量的禽类重复该方案.定量血浆头孢噻呋游离酸当量,并通过非房室药代动力学方法分析数据。10和20mg/kgCCFAIM给药的平均观察到的血浆峰值浓度为9.23µg/mL和15.08µg/mL,分别。达到最大血浆浓度的平均观察时间为18和17.6小时,肌内给药10和20mg/kgCCFA的平均末端消除半衰期为32.38和38.08小时,分别,在BAEAs中。先前研究中报告的raptor细菌分离株的最低抑制浓度用于确定本研究中选择的1µg/mL的目标最低抑制浓度。从以前发布的信息来看,BAEAs中CCFA的目标血浆浓度为4µg/mL。从这项研究的结果来看,CCFA可以每60和110小时给药10mg/kgIM,每80和160小时在BAEAs中20mg/kgIM。
The objective of this study was to evaluate the pharmacokinetic properties of ceftiofur crystalline free acid (CCFA) administered intramuscularly at dosages of 10 and 20 mg/kg in bald eagles (BAEAs) (Haliaeetus leucocephalus). Ceftiofur crystalline free acid is a long-acting, injectable, third-generation cephalosporin antibiotic drug. A prospective, randomized, complete crossover design was used for this pharmacokinetic investigation. CCFA (10 or 20 mg/kg) was administered intramuscularly, and blood samples were obtained from 6 adult, nonreleasable, healthy BAEAs at predetermined sampling times. After a 4-week washout period, the protocol was repeated with each bird receiving the dose not given during the initial sample collection according to the randomized crossover design. Plasma ceftiofur free acid equivalents were quantified and data were analyzed by a noncompartmental pharmacokinetic approach. The mean observed peak plasma concentrations were 9.23 µg/mL and 15.08 µg/mL for 10 and 20 mg/kg CCFA IM administration, respectively. The mean observed time to maximum plasma concentration was 18 and 17.6 hours, and the mean terminal elimination half-life was 32.38 and 38.08 hours for intramuscular administration of 10 and 20 mg/kg CCFA, respectively, in the BAEAs. Reported minimum inhibitory concentrations of raptor bacterial isolates from a prior study was used to determine the target minimum inhibitory concentration of 1 µg/mL selected for this investigation. From the previously published information, a target plasma concentration of 4 µg/mL was determined for the CCFA in the BAEAs. From the results of this study, CCFA may be dosed every 60 and 110 hours at 10 mg/kg IM, and every 80 and 160 hours at 20 mg/kg IM in BAEAs.